Ask AI
ProCE Banner Activity

Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

Conference Coverage
Podcast Episodes

In this podcast episode, listen to Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, discuss key updates and new clinical trial data for gynecologic cancers presented at the 2023 ASCO Annual Meeting, including final overall survival data from KEYNOTE-826; a study from the Canadian Cancer Trials Network on radical vs simple  hysterectomy in locally advanced, recurrent cervical cancers; and new data for novel combinations of immunotherapy plus PARP inhibitors in ovarian and endometrial cancer.

Released: June 22, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor, University Milano-Bicocca
Director, Gynecologic Oncology Program
Director, Division of Medical Gynecologic Oncology
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Immunogen Merck Sharp & Doheme, Mersana, Nuvation, Oncxerna, Pfizer, Pieris, Roche.

Kathleen N. Moore, MD, MS, FASCO

Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology
University of Oklahoma, HSC
Oklahoma City, Oklahoma

Kathleen Moore, MD: consultant/advisor/speaker: Aadi, Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Caris, Clovis, Eisai, Genentech/Roche, GlaxoSmithKline, Hengrui, Immunogen, Lilly, Mereo, Merck, Mersana, Myriad, Novartis, Onconova, OncXerna, Panavance, VBL Therapeutics, Verastem.